Document Detail


Denosumab for postmenopausal osteoporosis?
MedLine Citation:
PMID:  22241889     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Osteoporosis is the most common clinical disorder of bone metabolism, and is characterised by low bone mass and deterioration of the microarchitecture of bone tissue that results in increased bone fragility and susceptibility to bone fracture. In the UK, it is estimated that osteoporosis affects over 3 million people and leads to 230,000 fractures per year. It occurs most commonly in postmenopausal women and prevalence increases markedly with age, from 2% in women at 50 years to more than 25% at 80 years of age. Denosumab (Prolia - Amgen) is a monoclonal antibody that decreases bone resorption. It has been licensed in the EU for the treatment of osteoporosis in postmenopausal women at increased risk of fractures, and also for the treatment of bone loss associated with hormone ablation in men with prostate cancer at increased risk of fractures. Here, we review the role of denosumab in the management of postmenopausal osteoporosis.
Authors:
-
Related Documents :
24683429 - Revision total hip arthroplasty combined with subtrochanteric shortening osteotomy: cas...
24174079 - Rhinoplasty in the "chata" nose of the caribbean.
23158369 - The concept of ankle joint preserving surgery: why does supramalleolar osteotomy work a...
24326359 - Tension band wiring in olecranon fractures: the myth of technical simplicity and osteos...
17623239 - Biomechanical analyses of mesh fixation in tapp and tep hernia repair.
21757929 - Determination of clinical decision rule for estimation of bone mineral density in women.
14736479 - Unreamed femoral nail with spiral blade in subtrochanteric fractures: experience of 55 ...
23365149 - Effect on bone turnover markers of once-yearly intravenous infusion of zoledronic acid ...
15125019 - Hoechst 33342 is a useful cell tracer for a long-term investigation of articular cartil...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Drug and therapeutics bulletin     Volume:  50     ISSN:  1755-5248     ISO Abbreviation:  Drug Ther Bull     Publication Date:  2012 Jan 
Date Detail:
Created Date:  2012-01-13     Completed Date:  2012-03-13     Revised Date:  2013-06-03    
Medline Journal Info:
Nlm Unique ID:  0112037     Medline TA:  Drug Ther Bull     Country:  England    
Other Details:
Languages:  eng     Pagination:  6-8     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Aged, 80 and over
Alendronate / therapeutic use
Antibodies, Monoclonal / adverse effects,  therapeutic use*
Antibodies, Monoclonal, Humanized
Bone Density / drug effects
Bone Density Conservation Agents / adverse effects,  therapeutic use*
Female
Humans
Middle Aged
Osteoporosis, Postmenopausal / drug therapy*
Practice Guidelines as Topic
Chemical
Reg. No./Substance:
0/Antibodies, Monoclonal; 0/Antibodies, Monoclonal, Humanized; 0/Bone Density Conservation Agents; 4EQZ6YO2HI/denosumab; 66376-36-1/Alendronate

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Placental Hypoxia and Foetal Development Versus Alcohol Exposure in Pregnancy.
Next Document:  Herbal medicines for osteoarthritis.